Reporting OR (ROR) of COVID-19 vaccines and all other vaccines in subgroup analysis
| Type of analysis | ILD cases | Non-cases | ROR (95% CI) |
| Subgroup analysis | |||
| Age | |||
| Age <65 (case=315, non-case=3150) | |||
| The other vaccines | 36 (11.4) | 339 (10.8) | Reference |
| COVID-19 vaccines | 268 (85.1) | 2447 (77.7) | 0.94 (0.65 to 1.35) |
| Age ≥65 (case=364, non-case=3640) | |||
| The other vaccines | 17 (4.7) | 120 (3.3) | Reference |
| COVID-19 vaccines | 347 (95.3) | 3520 (96.7) | 0.70 (0.41 to 1.17) |
| Gender | |||
| Male (case=356, non-case=3560) | |||
| The other vaccines | 31 (8.7) | 254 (7.1) | Reference |
| COVID-19 vaccines | 325 (91.3) | 3306 (92.9) | 0.81 (0.55 to 1.19) |
| Female (case=323, non-case=3230) | |||
| The other vaccines | 22 (6.8) | 205 (6.4) | Reference |
| COVID-19 vaccines | 301 (93.2) | 3025 (93.7) | 0.93 (0.59 to 1.46) |
| Region | |||
| Western Pacific region (case=30, non-case=933) | |||
| The other vaccines | 5 (16.7) | 73 (7.8) | Reference |
| COVID-19 vaccines | 25 (83.3) | 860 (92.2) | 0.42 (0.16 to 1.14) |
| The other regions (case=649, non-case=5857) | |||
| The other vaccines | 48 (7.4) | 386 (6.6) | Reference |
| COVID-19 vaccines | 601 (92.6) | 5471 (93.4) | 0.88 (0.65 to 1.21) |
ILD, interstitial lung disease.